Transmitted HIV-1 Drug-resistance Mutations among Newly Diagnosed Patients of the North Western Region of Cameroon
International Journal of TROPICAL DISEASE & Health,
Background: First line antiretroviral treatment (ART) regimens in Cameroon comprises of reverse transcriptase inhibitors (RTIs). As ART continues to expand, the emergence of HIV drug resistance mutations (DRMs) is a challenging problem. The ongoing scale up of ART in Cameroon has prompted the interest in surveillance of transmitted drug resistance (TDR). The aim of this study was to evaluate the prevalence of TDR among drug naïve individuals residing in the North West Region (NWR) of Cameroon.
Methods: Ethics approval was obtained from the National Ethics Committee of Cameroon and patients informed consents were obtained. A total of 81 HIV-1 infected and drug naïve patients were recruited from randomly selected clinics located in the NWR of Cameroon from February 2016 and April 2016. HIV-1 protease-reverse transcriptase region was sequenced using an in-house protocol. HIV drug resistance mutations were identified and analyzed using Stanford HIVDR database and the Calibrated Population Resistance (CPR) tools. Data was analyzed using SPSS version 23.
Results: Of the 81 samples analyzed, the prevalence of TDR was 11.1% (9/81). Of these 9.9% (8/81) had drug resistance mutations to nucleoside and non-nucleoside reverse transcriptase inhibitors (NRTIs and NNRTIs) and a single individual (1.2%) with protease inhibitors. A total of 8.6 % (7/81), 4.9(4/81), and 3.7 % (3/81) individuals had a major mutation to NRTIs, NNRTIs, and both NRTIs and NNRTIs respectively. Thymidine analogue mutations [TAM] (M41ML, D67N, K70T/R, T215TA/F, and K219Q) were detected in five individuals. The most frequent NRTI and NNRTI DRMs were K219Q (n=2) and E138A (n=2) respectively. Mutations associated with NRTIs were TAM and M184MV; NNRTIs were A98G, K103N, V108I, V179E, and Y181C and I54IFV for PI. CPR tool revealed a 4.9% (4/81) prevalence with the following single mutations K103N D67N, K70R, M184V, T215F, K219Q.The difference between two methods was statistically significant p=0.0001. These mutations confer resistance to all NRTIs and NNRTIs drugs.
Conclusions: Although moderate transmitted drug resistance (11.1%) levels were detected in this study, this calls for routine drug resistance surveillance among patients on ART. This will ensure relative maintenance of low viral suppression amongst HIV patients.
- HIV-1, Antiretroviral therapy, transmitted Drug resistance, Cameroon
How to Cite
Caceres C, O’Reilly K, Mayer K, Baggaley. PrEP implementation: moving from trials to policy and practice. Journal of the International AIDS Society. 2015;18(Suppl 3):20222.
Onywera H, Maman D, Inzaule S, Auma E, Were K, Fredrick H, et al. Surveillance of HIV-1 pol transmitted drug resistance in acutely and recently infected antiretroviral drug-naive persons in rural western Kenya. PloS One. 2017;12(2):e0171124.
Burda ST, Viswanath R, Zhao J, Kinge T, Anyangwe C, Tinyami ET, et al. HIV-1 reverse transcriptase drug-resistance mutations in chronically infected individuals receiving or naive to HAART in Cameroon. J med virol. 2010;82(2):187-96.
Minister of Public Health. National Guidelines on the Prevention and Management of HIV in Cameroon; 2015.
Accessed 12 November 2017
Laurent C, Meilo, H, Guiard-Schmid J, Mapoure Y, Noel J, M'Bangue M, et al. Antiretroviral therapy in public and private routine health care clinics in Cameroon: lessons from the Douala antiretroviral (DARVIR) initiative. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2005;41:108-111.
Teto G, Tagny C, Mbanya D, Fonsah J, Fokam J, Nchindap E, et al. Gag P2/NC and pol genetic diversity, polymorphism, and drug resistance mutations in HIV-1 CRF02_AG- and non-CRF02_AG-infected patients in Yaounde, Cameroon. Scientific Reports. 2017;7(1):14136.
Fokam J, Bellocchi M, Armenia D, Nanfack A, Carioti L, Continenza F, et al. Next-generation sequencing provides an added value in determining drug resistance and viral tropism in Cameroonian HIV-1 vertically infected children. Medicine. 2018;97(13):e0176.
Kalua T, Barr B, van Oosterhout J, Mbori-Ngacha D, Schouten E, Gupta S, et al. Lessons learned from option B+ in the evolution toward “Test and Start ” From Malawi, Cameroon, and the United Republic of Tanzania. J Acquir Immune Defic Syndr. 2017;75:S43–S50
WHO. Summary country profile for HIV/AIDS treatment scale-up; 2005.
Billong S, Fokam J, Penda C, Amadou S, Kob D, Billong E, et al. Predictors of poor retention on antiretroviral therapy as a major HIV drug resistance early warning indicator in Cameroon: results from a nationwide systematic random sampling. BMC Infect Dis. 2016;16(1):678.
Fokam J, Takou D, Santoro M, Akonie H, Kouanfack C, Ceccherini-Silberstein, F. (). Population-Based Surveillance of HIV-1 drug resistance in Cameroonian adults initiating antiretroviral therapy according to the World Health Organization guidelines. AIDS Research on Human Retroviruses. 2015;32(4):29 333.
Pennings P. HIV drug resistance: Problems and perspectives. Infectious disease reports 2013; 5:e5.
Xiaobai Z, Xi C, Tian H, Williams A, Wang H, He J, et al. Prevalence of WHO transmitted drug resistance mutations by deep sequencing in antiretroviral-naive subjects in Hunan Province, China. PloS One. 2014;9:e98740.
Ceccarelli L, Salpini R, Moudourou S, Cento V, Santoro MM, Fokam J, et al. Characterization of drug resistance mutations in naive and ART-treated patients infected with HIV-1 in Yaounde, Cameroon. Journal of Medical Virology. 2012;84:721-727.
Aghokeng AF, Kouanfack C, Eymard-Duvernay S, Butel C, Edoul GE, Laurent C, et al. Virological outcome and patterns of HIV-1 drug resistance in patients with 36 months' antiretroviral therapy experience in Cameroon. JIAS. 2013;16:18004.
Zoufaly A, Jochum J, Hammerl R, Nassimi N, Raymond Y, Burchard G, et al. Determinants of HIV-1 drug resistance in treatment-naive patients and its clinical implications in an antiretroviral treatment program in Cameroon. J Int AIDS Soc. 2014;17(4 Suppl 3):19615.
Bosire E, Nyamache A, Gicheru M, Khamadi S, Lihana R, Okoth V. Population specific reference ranges of CD3, CD4 and CD8 lymphocyte subsets among healthy Kenyans. AIDS Res Ther. 2013;10(1):24.
Fokam J, Salpini R, Santoro MM, Cento V, D’Arrigo R, Gori C, et al. Performance evaluation of an in-house human immunodeficiency virus type-1 protease-reverse transcriptase genotyping assay in Cameroon. Arch Virol. 2011;156:1235–43.
Accessed 9 May 2017
Available:https://www hivdb.stanford.edu/hivdb/by-sequences. Accessed 6 February 2018
Accessed 6 February 2018
Tchouwa G, Eymard-Duvernay S, Cournil A, Lamare N, Serrano L, Butel C, et al. Prevalence of pretreatment HIV drug resistance in Cameroon following a nationally representative WHO survey. J Antimicrob Chemother; 2018.
Agyingi L, Mayr L, Kinge T, Orock G, Ngai J, Asaah B, et al. The evolution of HIV-1 group M genetic variability in Southern Cameroon is characterized by several emerging recombinant forms of CRF02_AG and viruses with drug resistance mutations. J Med Virol. 2014; 86(3):385-93.
Vessiere A, Nerrienet E, Kfutwah A, Menu E, Tejiokem M, Pinson-Recordon P, et al. HIV-1 pol gene polymorphism and antiretroviral resistance mutations in drug-naive pregnant women in Yaounde, Cameroon. Journal of Acquired Immune Deficiency Syndromes. 2006;42(2):256-258.
Chaplin B, Eisen G, Idoko J, Onwujekwe D, Idigbe E, Adewole I, et al. Impact of HIV Type 1 subtype on drug resistance mutations in Nigerian patients failing first-line therapy. AIDS Research and Human Retroviruses. 2011;27(1):71-80.
Wensing A, Calvez V, Gunthard H, Johnson V, Paredes R, Pillay D, et al. Update of the drug resistance mutations in HIV-1. Top Antivir Med. 2017;24(4):132-133.
De Luca A, Sidumo Z, Zanelli G, Magid N, Luhanga R, Brambilla D, et al. Accumulation of HIV-1 drug resistance in patients on a standard thymidine analogue-based first line antiretroviral therapy after virological failure: implications for the activity of next-line regimens from a longitudinal study in Mozambique. BMC Infect Dis. 2017;17(1):605.
Elmi Abar A, Jlizi A, Darar H, Kacem M, Slim A. HIV-1 drug resistance genotyping from antiretroviral therapy (ART) naive and first-line treatment failures in Djiboutian patients. Diagnostic Pathology. 2012; 7(1):138.
Kleyn T, Liedtke M, Harrison D, Lockhart S, Salvaggio M, et al. Incidence of transmitted antiretroviral drug resistance in treatment-naive HIV-1-infected persons in a large South Central United States clinic. Annals of Pharmacotherapy. 2014;48(4): 470-475.
Parczewski M, Leszczyszyn-Pynka M, Witak-Jedram M, Maciejewska K, Rymer W, Szymczak A, et al. Transmitted HIV drug resistance in antiretroviral treatment naïve patients from Poland differs by transmission category and subtypes. Journal of Antimicrobial Chemotherapy. 2015;70(1):233–242.
Konings F, Zhong P, Agwara M, Agyingi L, Zekeng L, Achkar J et al. Protease mutations in HIV-1 non-B strains infecting drug-naive villagers in Cameroon. AIDS Research and Human Retroviruses. 2004;20. 105-109.
Ndembi N, Abraha A, Pilch H, Ichimura H, Mbanya D, Kaptue L, et al. Molecular characterization of human immunodeficiency virus type 1 (HIV-1) and HIV-2 in Yaounde, Cameroon: evidence of major drug resistance mutations in newly diagnosed patients infected with subtypes other than subtype B. J Clin Microbiol. 2008;46(1):177-84.
Onywera H, Maman D, Inzaule S, Auma E, Were K, Fredrick H, et al. Surveillance of HIV-1 pol transmitted drug resistance in acutely and recently infected antiretroviral drug-naive persons in rural western Kenya. PLoS One. 2017;12(2), e0171124.
Xiaobai Z, Xi C, Tian H, Williams AB, Wang H, He J, et al. Prevalence of WHO transmitted drug resistance mutations by deep sequencing in antiretroviral-naïve subjects in Hunan Province, China. PLoS One. 2014 Jun 4;9(6):e98740.
Rodes B, García F, Gutierrez C, Martinez‐Picado J, Aguilera A, Saumoy M, et al. Impact of drug resistance genotypes on CD4+ counts and plasma viremia in heavily antiretroviral‐experienced HIV‐infected patients. Journal of Medical Virology. 2005;77(1):23-8.
Brooks K, Diero L, DeLong A, Balamane M, Reitsma M, Kemboi E, et al. Treatment failure and drug resistance in HIV‐positive patients on tenofovir‐based first‐line antiretroviral therapy in western Kenya. Journal of the International AIDS Society. 2016 19(1):20798.
Abstract View: 65 times
PDF Download: 19 times